Source: Globe Newswire
PetVivo Holdings, Inc. has signed an Exclusive License and Supply Agreement with VetStem, Inc. to commercialize PrecisePRP®, an innovative off-the-shelf platelet-rich plasma (PRP) product for dogs and horses. Unlike traditional PRP kits, PrecisePRP® does not require blood draws or centrifugation, ensuring consistent dosing and ease of use for veterinarians.
The product, which is FDA-reviewed, contains 4 billion platelets per vial and is leucoreduced to minimize safety risks. Rigorous screening of donor animals, including FDA CVM Guidance 254 compliance, ensures low transfusion reaction risks. Clinical studies found no treatment-related adverse events in dogs or horses. PetVivo Board Member Mike Eldred called PrecisePRP® a game-changer, aligning with PetVivo’s vision for advancing regenerative veterinary medicine. The company will integrate PrecisePRP® with Spryng™ with OsteoCushion™ Technology, an intra-articular injectable designed to improve joint mechanics and alleviate pain in animals with osteoarthritis and joint instability.